Azienda Ospedaliera Papa Giovanni XXIII

At Azienda Ospedaliera Papa Giovanni XXIII in Bergamo, research in hemic and lymphatic diseases and neoplasms is strongly focused on blood cancers. Studies are exploring new immune-based and targeted approaches for large B-cell lymphoma, relapsed or refractory non-Hodgkin’s lymphoma, acute myeloid leukemia, chronic myelomonocytic leukemia, and acute lymphoblastic leukemia, with the goal of improving treatment effectiveness and safety in difficult-to-treat disease.

• Testing novel therapies for relapsed or refractory lymphoma and leukemia
• Evaluating immune-based treatment combinations for better cancer control
• Assessing new options for patients with limited standard treatment choices

These trials reflect a broad effort to advance hematology-oncology care through more precise and potentially more effective therapies.

The site also contributes to research in neoplasms affecting the breast, stomach, lung, and skin. Clinical trials are studying locally advanced or metastatic breast cancer, gastric or gastroesophageal cancer, unresectable non-small cell lung cancer, and melanoma, often with an emphasis on tailored treatment strategies and improved outcomes after standard therapy.

• Exploring new treatment approaches for advanced breast cancer and gastric cancer
• Evaluating immunotherapy combinations in non-small cell lung cancer
• Studying patient preferences for different treatment delivery methods in melanoma

These studies aim to refine cancer care by testing whether newer therapies can better control disease and support personalized treatment decisions.

Clinical trials in cardiovascular diseases, nutritional and metabolic diseases, and metabolism address common chronic conditions with major long-term impact. Research includes heart failure, heart failure with preserved ejection fraction, type 2 diabetes, and chronic kidney disease with high proteinuria, focusing on better disease control and slowing progression.

• Testing new therapies for heart failure and HFpEF
• Comparing treatments to improve blood sugar control in type 2 diabetes
• Studying approaches to slow kidney function decline in chronic kidney disease

This research supports efforts to improve everyday management of chronic cardiometabolic illness and reduce complications over time.

Work in immune system diseases includes trials for chronic graft versus host disease, while additional studies address rare conditions such as severe Crigler-Najjar syndrome. The research also connects to broader metabolic and virus diseases interests, showing a diverse portfolio beyond oncology and cardiology.

• Evaluating new options for chronic graft versus host disease
• Investigating gene therapy for a rare inherited liver disorder
• Assessing treatments for patients with limited established therapies

These studies aim to improve symptom control, disease management, and long-term outcomes in conditions that often require specialized care.

At this hospital site, research also extends to respiratory tract diseases and virus diseases. Current trials include idiopathic pulmonary fibrosis and HIV, with a focus on finding better ways to slow lung decline and support effective long-term viral treatment.

• Studying therapies for idiopathic pulmonary fibrosis
• Comparing treatment strategies for people living with HIV
• Assessing whether newer options can improve disease control and quality of life

These investigations combine chronic disease management with the search for safer, more effective treatment strategies.